

PRESS RELEASE
17 June 2023 10:30:00 CEST



Schelin Catheter® has been approved in Switzerland

ProstaLund AB announces today that the product Schelin Catheter® has been registered and approved for sale in Switzerland. At the same time, the company has signed a couple of distribution agreements with some distributors. The first orders will be delivered during the current quarter.

ProstaLund has previously signed distribution agreements for the UK, Italy, Poland and Spain in Europe for its Stand-Alone products, Schelin Catheter® and CoreFlow® Soft Stent.

- "Switzerland is not, and will not be, a large market for us, but it is interesting from many other aspects. One aspect is that it is a multi-language country. That's also one of the reasons we didn't sign an exclusive agreement with only one party, but a couple. It will also mean that we will get both German-speaking and French-speaking reference clinics in the near future, which enables continued expansion in the surrounding countries. The fact that Switzerland is not part of the EU and has its own regulatory rules means that we have only chosen at this stage to go in with Schelin Catheter®. Switzerland is also a country where high quality products and services are appreciated and I can very well imagine that it could become a country for our treatment method when we later roll out CoreTherm® Eagle in Europe," says CEO Johan Wennerholm in a comment.

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se



PRESS RELEASE
17 June 2023 10:30:00 CEST

Attachments

Schelin Catheter® has been approved in Switzerland